What is Exelixis Inc's earnings per share (EPS)?

Exelixis Inc (EXEL) reported diluted earnings per share of $2.78 for fiscal year 2025. This represents a 58.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Exelixis Inc Financials

EXEL

Trailing 12 months to July 3, 2026

Revenue $2.4B +9.2% YoY

Net Income $860.7M +42.9% YoY

EPS (Diluted) $3.18 +52.9% YoY

Free Cash Flow $1.2B +55.5% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2027, ended Jul 3, 2026 Reported Aug 5, 2026 Currency USD FYE January

Exelixis Inc (EXEL) reported $2.4B in revenue over the twelve months to Jul 3, 2026, up 9.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EXEL FY2025 2026-08-30

Operating leverage is turning stable gross economics into faster profit and cash growth while buybacks reduce the share base.

From FY2024 to FY2025, revenue rose 7.0% while operating margin widened, showing that additional sales dropped through to profit more efficiently. R&D fell from $910M to $825M as revenue rose, reinforcing that the step-up came below gross profit rather than from improved product-level economics.

Operating cash flow was $884M versus net income of $783M, so reported earnings were accompanied by greater cash realization. Free cash flow reached $876M while capital expenditures were only $8M; capital intensity is low relative to earnings.

Buybacks of $948M reduced shares outstanding by 7.2%, showing that cash generation was being returned rather than retained. Debt-to-equity remained at 0.3x and the current ratio at 3.6x, so capital allocation occurred without a visible shift toward heavier leverage or short-term strain.

Financial Health Signals

Financial Health Score 80/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Exelixis Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Exelixis Inc has an operating margin of 37.6%, meaning the company retains $38 of operating profit per $100 of revenue. This strong profitability earns a score of 82/100, reflecting efficient cost management and pricing power. This is up from 27.9% the prior year.

Growth

Exelixis Inc's revenue grew 7.0% year-over-year to $2.3B, a solid pace of expansion. This earns a growth score of 71/100.

Leverage

Exelixis Inc carries a low D/E ratio of 0.32, meaning only $0.32 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 68/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.56, Exelixis Inc holds $3.56 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 82/100.

Cash Flow

Exelixis Inc converts 37.8% of revenue into free cash flow ($875.8M). This strong cash generation earns a score of 95/100.

Returns

Exelixis Inc earns a strong 36.2% return on equity (ROE), meaning it generates $36 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 79/100. This is up from 23.2% the prior year.

Altman Z-Score Safe

14.08

Exelixis Inc scores 14.08, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($13.5B) relative to total liabilities ($683.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

Exelixis Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.13x

For every $1 of reported earnings, Exelixis Inc generates $1.13 in operating cash flow ($884.3M OCF vs $782.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.3B

YoY+7.0%

5Y CAGR+18.6%

10Y CAGR+51.2%

Exelixis Inc generated $2.3B in revenue in fiscal year 2025. This represents an increase of 7.0% from the prior year.

EBITDA

$901.2M

YoY+42.3%

5Y CAGR+49.9%

Exelixis Inc's EBITDA was $901.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 42.3% from the prior year.

Net Income

$782.6M

YoY+50.1%

5Y CAGR+47.6%

Exelixis Inc reported $782.6M in net income in fiscal year 2025. This represents an increase of 50.1% from the prior year.

EPS (Diluted)

$2.78

YoY+58.0%

5Y CAGR+51.4%

Exelixis Inc earned $2.78 per diluted share (EPS) in fiscal year 2025. This represents an increase of 58.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$875.8M

YoY+30.4%

5Y CAGR+37.4%

Exelixis Inc generated $875.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 30.4% from the prior year.

Cash & Debt

$482.5M

YoY+122.0%

5Y CAGR+8.6%

10Y CAGR+13.0%

Exelixis Inc held $482.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

260M

YoY-7.2%

5Y CAGR-3.6%

10Y CAGR+1.3%

Exelixis Inc had 260M shares outstanding in fiscal year 2025. This represents a decrease of 7.2% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

96.4%

YoY-0.1pp

5Y CAGR+0.1pp

10Y CAGR+6.9pp

Exelixis Inc's gross margin was 96.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the prior year.

Operating Margin

37.6%

YoY+9.7pp

5Y CAGR+26.5pp

Exelixis Inc's operating margin was 37.6% in fiscal year 2025, reflecting core business profitability. This is up 9.7 percentage points from the prior year.

Net Margin

33.7%

YoY+9.7pp

5Y CAGR+22.4pp

Exelixis Inc's net profit margin was 33.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 9.7 percentage points from the prior year.

Return on Equity

36.2%

YoY+13.0pp

5Y CAGR+30.3pp

Exelixis Inc's ROE was 36.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 13.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$825.0M

YoY-9.4%

5Y CAGR+8.5%

10Y CAGR+24.0%

Exelixis Inc invested $825.0M in research and development in fiscal year 2025. This represents a decrease of 9.4% from the prior year.

Share Buybacks

$947.5M

YoY+45.3%

Exelixis Inc spent $947.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 45.3% from the prior year.

Capital Expenditures

$8.4M

YoY-70.4%

5Y CAGR-22.6%

10Y CAGR+34.1%

Exelixis Inc invested $8.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 70.4% from the prior year.

EXEL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EXEL quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$2.4B	$2.3B+7.0%	$2.2B+18.5%	$1.8B+13.6%	$1.6B+12.3%	$1.4B+45.3%	$987.5M+2.0%	$967.8M+13.3%	$853.8M+88.7%	$452.5M+136.3%	$191.5M+415.0%	$37.2M+48.0%	$25.1M-19.9%	$31.3M-34.0%	$47.5M-83.6%	$289.6M
Cost of Revenue	$85.7M	$83.7M+9.8%	$76.2M+5.1%	$72.5M+25.3%	$57.9M+9.5%	$52.9M+45.8%	$36.3M+9.6%	$33.1M+25.6%	$26.3M+74.9%	$15.1M+129.9%	$6.6M+68.2%	$3.9M+90.7%	$2.0M+82.7%	$1.1M	$0	$0
Gross Profit	$2.4B	$2.2B+6.9%	$2.1B+19.0%	$1.8B+13.2%	$1.6B+12.4%	$1.4B+45.3%	$951.3M+1.8%	$934.7M+13.0%	$827.5M+89.2%	$437.4M+136.6%	$184.9M+455.6%	$33.3M+44.3%	$23.1M-23.7%	$30.2M-36.3%	$47.5M-83.6%	$289.6M
R&D Expenses	$824.3M	$825.0M-9.4%	$910.4M-12.8%	$1.0B+17.1%	$891.8M+28.6%	$693.7M+26.6%	$547.9M+62.6%	$337.0M+84.9%	$182.3M+62.5%	$112.2M+16.9%	$96.0M-0.4%	$96.4M-49.0%	$189.1M+5.8%	$178.8M+38.7%	$128.9M-17.8%	$156.8M
SG&A Expenses	$533.9M	$518.7M+5.4%	$492.1M-9.3%	$542.7M+18.0%	$459.9M+14.5%	$401.7M+36.9%	$293.4M+28.5%	$228.2M+10.6%	$206.4M+29.5%	$159.3M+37.2%	$116.1M+102.7%	$57.3M+12.7%	$50.8M-0.3%	$51.0M+60.1%	$31.8M-3.9%	$33.1M
Operating Income	$971.5M	$872.2M+44.3%	$604.6M+253.8%	$170.9M-15.2%	$201.5M-29.7%	$286.7M+160.5%	$110.1M-70.2%	$369.5M-15.8%	$438.9M+164.5%	$165.9M+689.9%	-$28.1M+76.8%	-$121.4M+45.9%	-$224.5M-11.8%	-$200.7M-63.9%	-$122.4M-236.7%	$89.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$8.7M-73.7%	$33.1M-18.7%	$40.7M-1.6%	$41.4M+6.7%	$38.8M+56.5%	$24.8M+52.4%	$16.3M
Income Tax	$174.8M	$158.6M-1.1%	$160.4M+222.3%	$49.8M-4.4%	$52.1M-17.5%	$63.1M+231.1%	$19.1M-75.3%	$77.1M+132.4%	-$238.0M-5570.8%	$4.3M	$0-100.0%	$55K+130.2%	-$182K-89.6%	-$96K-189.7%	$107K-91.7%	$1.3M
Net Income	$860.7M	$782.6M+50.1%	$521.3M+150.9%	$207.8M+14.0%	$182.3M-21.1%	$231.1M+106.7%	$111.8M-65.2%	$321.0M-53.5%	$690.1M+347.4%	$154.2M+319.6%	-$70.2M+56.6%	-$161.7M+38.1%	-$261.3M-9.7%	-$238.2M-63.9%	-$145.3M-292.0%	$75.7M
EPS (Diluted)	$3.18	$2.78+58.0%	$1.76+170.8%	$0.65+16.1%	$0.56-22.2%	$0.72+105.7%	$0.35-65.7%	$1.02-53.8%	$2.21+351.0%	$0.49+275.0%	-$0.28+63.6%	-$0.77	N/A	-$1.33-44.6%	-$0.92-258.6%	$0.58

Metric	Q2'27	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25
Revenue	$628.7M+2.9%	$610.8M+2.0%	$598.7M+0.2%	$597.8M+5.2%	$568.3M+2.3%	$555.4M-2.0%	$566.8M+5.0%	$539.5M
Cost of Revenue	$20.7M+3.5%	$20.0M-24.7%	$26.5M+42.6%	$18.6M-4.6%	$19.5M+1.6%	$19.2M-4.0%	$20.0M+15.2%	$17.3M
Gross Profit	$608.0M+2.9%	$590.9M+3.3%	$572.2M-1.2%	$579.2M+5.5%	$548.8M+2.3%	$536.3M-1.9%	$546.8M+4.7%	$522.2M
R&D Expenses	$212.0M+6.0%	$199.9M-6.3%	$213.2M+7.1%	$199.2M-0.6%	$200.4M-5.6%	$212.2M-14.8%	$249.0M+11.9%	$222.6M
SG&A Expenses	$147.6M+5.8%	$139.6M+13.5%	$123.0M-0.5%	$123.7M-8.3%	$134.9M-1.7%	$137.2M+2.1%	$134.3M+20.1%	$111.8M
Operating Income	$248.4M-1.2%	$251.3M+6.9%	$235.2M-0.6%	$236.5M+10.8%	$213.6M+14.3%	$186.9M+14.5%	$163.2M+19.9%	$136.1M
Income Tax	$50.6M-11.5%	$57.2M+601.2%	$8.2M-86.1%	$58.8M+29.1%	$45.6M-1.1%	$46.1M+2.6%	$44.9M+22.1%	$36.8M
Net Income	$212.1M+0.8%	$210.5M-13.9%	$244.6M+26.3%	$193.6M+4.7%	$184.8M+15.8%	$159.6M+14.1%	$139.9M+18.6%	$118.0M
EPS (Diluted)	$0.82+3.8%	$0.79-10.2%	$0.88+27.5%	$0.69+6.2%	$0.65+18.2%	$0.55+14.6%	$0.48+20.0%	$0.40

Not reported in any period shown, so not listed: Interest Expense.

EXEL Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EXEL quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$2.8B-3.5%	$2.9B+0.2%	$2.9B-4.2%	$3.1B+17.4%	$2.6B+22.4%	$2.1B+13.3%	$1.9B+32.6%	$1.4B+117.0%	$655.3M+10.0%	$595.7M+79.3%	$332.3M+2.8%	$323.3M-35.8%	$503.3M-30.2%	$721.1M+83.4%	$393.3M
Current Assets	$1.4B-1.7%	$1.5B+11.4%	$1.3B-18.6%	$1.6B-11.8%	$1.8B+26.9%	$1.4B+42.9%	$1.0B+12.7%	$897.0M+85.0%	$484.9M+3.4%	$469.0M+162.5%	$178.7M+6.8%	$167.2M-37.3%	$266.6M-38.4%	$432.5M+89.0%	$228.8M
Cash & Equivalents	$482.5M+122.0%	$217.4M-17.3%	$263.0M-47.5%	$501.2M-22.6%	$647.2M+102.7%	$319.2M+19.8%	$266.5M-15.3%	$314.8M+71.9%	$183.2M+20.8%	$151.7M+7.1%	$141.6M+76.2%	$80.4M-22.7%	$104.0M-38.9%	$170.1M+129.0%	$74.3M
Inventory	$21.7M-3.1%	$22.4M+29.2%	$17.3M-48.0%	$33.3M+21.1%	$27.5M+31.1%	$21.0M+62.8%	$12.9M+31.0%	$9.8M+47.8%	$6.7M+99.4%	$3.3M+27.6%	$2.6M+9.9%	$2.4M-17.6%	$2.9M	$0	N/A
Goodwill	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M
Total Liabilities	$683.1M-2.9%	$703.5M+3.7%	$678.4M+16.4%	$583.1M+43.7%	$405.6M+57.1%	$258.2M+29.3%	$199.7M+48.1%	$134.8M-63.6%	$370.3M-26.9%	$506.4M+7.0%	$473.1M-2.0%	$482.6M-0.2%	$483.5M+1.6%	$476.0M+57.3%	$302.6M
Current Liabilities	$405.6M+0.5%	$403.8M+2.4%	$394.3M+21.6%	$324.4M-3.9%	$337.6M+65.0%	$204.7M+43.4%	$142.7M+35.3%	$105.5M-8.4%	$115.2M-57.2%	$268.8M+414.4%	$52.3M-69.3%	$170.4M+94.0%	$87.9M+7.5%	$81.7M-11.5%	$92.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$417.9M+61.3%	$259.1M-22.8%	$335.5M+4.0%	$322.6M+82.6%	$176.6M
Total Equity	$2.2B-3.7%	$2.2B-0.9%	$2.3B-9.0%	$2.5B+12.6%	$2.2B+17.6%	$1.9B+11.5%	$1.7B+31.0%	$1.3B+351.8%	$285.0M+219.0%	$89.3M+163.4%	-$140.8M+11.6%	-$159.3M-1198.9%	$14.5M-93.9%	$238.1M+162.7%	$90.6M
Retained Earnings	-$76.8M+22.1%	-$98.6M+43.1%	-$173.4M-406.5%	-$34.2M+84.2%	-$216.5M+51.6%	-$447.6M+20.0%	-$559.4M+36.5%	-$880.4M+43.9%	-$1.6B+20.8%	-$2.0B-3.7%	-$1.9B-9.2%	-$1.8B-17.5%	-$1.5B-19.0%	-$1.3B-13.1%	-$1.1B

Metric	Q2'27	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25
Total Assets	$2.5B-3.8%	$2.6B-8.8%	$2.8B+0.7%	$2.8B+5.4%	$2.7B-5.6%	$2.8B-3.7%	$2.9B-0.4%	$3.0B
Current Assets	$1.3B+3.5%	$1.2B-16.3%	$1.4B+2.9%	$1.4B+18.8%	$1.2B-15.4%	$1.4B-4.8%	$1.5B-5.3%	$1.5B
Cash & Equivalents	$281.4M+24.5%	$226.2M-53.1%	$482.5M+28.2%	$376.3M+128.8%	$164.4M-10.5%	$183.8M-15.5%	$217.4M-15.9%	$258.3M
Inventory	$28.7M+8.0%	$26.6M+22.7%	$21.7M-20.9%	$27.4M+16.7%	$23.5M-5.5%	$24.9M+11.0%	$22.4M+6.5%	$21.0M
Goodwill	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M0.0%	$63.7M
Total Liabilities	$650.5M-1.1%	$657.8M-3.7%	$683.1M+3.1%	$662.8M+2.8%	$644.5M-8.7%	$706.2M+0.4%	$703.5M+2.7%	$684.9M
Current Liabilities	$361.9M-2.4%	$371.0M-8.5%	$405.6M+8.5%	$373.8M+11.2%	$336.1M-15.8%	$399.1M-1.2%	$403.8M+2.4%	$394.3M
Total Equity	$1.8B-4.8%	$1.9B-10.4%	$2.2B0.0%	$2.2B+6.3%	$2.0B-4.6%	$2.1B-5.0%	$2.2B-1.4%	$2.3B
Retained Earnings	-$262.5M-21.7%	-$215.8M-180.9%	-$76.8M+27.6%	-$106.1M+51.7%	-$219.5M-34.4%	-$163.3M-65.5%	-$98.6M-9.3%	-$90.3M

Not reported in any period shown, so not listed: Accounts Receivable, Long-Term Debt.

EXEL Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EXEL quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$1.2B	$884.3M+26.3%	$700.0M+110.0%	$333.3M-8.1%	$362.6M-9.5%	$400.8M+91.8%	$209.0M-60.3%	$527.0M+26.8%	$415.7M+151.0%	$165.6M-19.7%	$206.3M+245.7%	-$141.6M+39.9%	-$235.4M-18.4%	-$198.8M-61.4%	-$123.1M+22.7%	-$159.2M
Capital Expenditures	$11.0M	$8.4M-70.4%	$28.4M-29.7%	$40.5M+46.1%	$27.7M-48.9%	$54.2M+78.7%	$30.3M+136.4%	$12.8M-61.5%	$33.3M+57.5%	$21.1M+1141.5%	$1.7M+281.0%	$447K-5.7%	$474K-78.2%	$2.2M-20.1%	$2.7M+174.2%	$991K
Free Cash Flow	$1.2B	$875.8M+30.4%	$671.5M+129.3%	$292.9M-12.6%	$334.9M-3.4%	$346.6M+94.0%	$178.6M-65.3%	$514.1M+34.4%	$382.4M+164.7%	$144.5M-29.4%	$204.6M+244.0%	-$142.0M+39.8%	-$235.9M-17.4%	-$200.9M-59.7%	-$125.9M+21.4%	-$160.2M
Investing Cash Flow	$93.0M	$350.4M+400.1%	-$116.8M-333.3%	-$27.0M+94.9%	-$524.4M-1122.9%	-$42.9M+67.3%	-$131.2M+77.7%	-$587.2M-97.2%	-$297.9M-909.5%	$36.8M+117.0%	-$216.0M-531.4%	$50.1M-65.8%	$146.3M+1.4%	$144.4M+155.6%	-$259.5M-404.2%	-$51.5M
Financing Cash Flow	-$1.2B	-$969.6M-54.2%	-$628.8M-15.2%	-$546.1M-93282.9%	$586K+104.0%	-$14.8M+41.1%	-$25.1M-300.2%	$12.6M+29.5%	$9.7M+105.7%	-$169.9M-958.0%	$19.8M-87.0%	$152.7M+133.2%	$65.5M+661.2%	-$11.7M-102.4%	$478.4M+155.1%	$187.5M
Share Buybacks	$1.1B	$947.5M+45.3%	$652.0M+18.5%	$550.4M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'27	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25
Operating Cash Flow	$307.7M+22.2%	$251.8M-24.5%	$333.5M+14.9%	$290.3M+492.6%	$49.0M-76.8%	$211.4M-12.0%	$240.3M-11.5%	$271.3M
Capital Expenditures	$6.8M+351.7%	$1.5M+30.4%	$1.2M-21.9%	$1.5M-47.8%	$2.8M-3.9%	$3.0M-25.8%	$4.0M-51.5%	$8.2M
Free Cash Flow	$300.9M+20.2%	$250.3M-24.7%	$332.4M+15.1%	$288.8M+525.8%	$46.2M-77.9%	$208.5M-11.8%	$236.3M-10.2%	$263.1M
Investing Cash Flow	$91.4M+279.0%	-$51.1M-287.5%	$27.2M+7.2%	$25.4M-89.8%	$248.0M+398.4%	$49.8M+153.4%	-$93.2M+57.1%	-$217.1M
Financing Cash Flow	-$343.9M+24.8%	-$457.1M-79.6%	-$254.6M-145.1%	-$103.9M+67.2%	-$316.3M-7.3%	-$294.8M-56.8%	-$188.0M-3401.2%	$5.7M
Share Buybacks	$323.0M-25.0%	$430.4M+67.1%	$257.6M+147.6%	$104.0M-65.5%	$301.9M+6.3%	$283.9M+49.1%	$190.4M+1496.5%	$11.9M

Not reported in any period shown, so not listed: Dividends Paid.

EXEL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

EXEL quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	96.4%-0.1pp	96.5%+0.4pp	96.0%-0.4pp	96.4%+0.1pp	96.3%0.0pp	96.3%-0.2pp	96.6%-0.3pp	96.9%+0.2pp	96.7%+0.1pp	96.6%+7.1pp	89.5%-2.3pp	91.9%-4.6pp	96.4%-3.6pp	100.0%0.0pp	100.0%
Operating Margin	37.6%+9.7pp	27.9%+18.5pp	9.3%-3.2pp	12.5%-7.5pp	20.0%+8.8pp	11.1%-27.0pp	38.2%-13.2pp	51.4%+14.7pp	36.7%+51.4pp	-14.7%	-326.7%	-893.9%	-640.5%	-258.0%	30.9%
Net Margin	33.7%+9.7pp	24.0%+12.7pp	11.3%0.0pp	11.3%-4.8pp	16.1%+4.8pp	11.3%-21.9pp	33.2%-47.7pp	80.8%+46.7pp	34.1%+70.8pp	-36.7%	-435.1%	-1040.6%	-760.1%	-306.3%	26.1%
Return on Equity	36.2%+13.0pp	23.2%+14.1pp	9.2%+1.9pp	7.3%-3.1pp	10.4%+4.5pp	5.9%-13.1pp	19.0%-34.6pp	53.6%-0.5pp	54.1%+132.7pp	-78.6%	N/A	N/A	-1642.9%-1581.9pp	-61.0%-144.6pp	83.5%
Return on Assets	27.5%+9.8pp	17.7%+10.6pp	7.1%+1.1pp	5.9%-2.9pp	8.8%+3.6pp	5.2%-11.8pp	17.0%-31.5pp	48.5%+25.0pp	23.5%+35.3pp	-11.8%+36.9pp	-48.7%+32.2pp	-80.8%-33.5pp	-47.3%-27.2pp	-20.2%-39.4pp	19.3%
Current Ratio	3.56-0.1x	3.63+0.3x	3.34-1.6x	4.99-0.4x	5.43-1.6x	7.060.0x	7.08-1.4x	8.50+4.3x	4.21+2.5x	1.74-1.7x	3.42+2.4x	0.98-2.1x	3.03-2.3x	5.29+2.8x	2.48
Debt-to-Equity	0.320.0x	0.310.0x	0.30+0.1x	0.23+0.1x	0.180.0x	0.140.0x	0.120.0x	0.10+0.1x	0.000.0x	0.00	N/A	N/A	23.14+21.8x	1.35-0.6x	1.95
FCF Margin	37.8%+6.8pp	31.0%+15.0pp	16.0%-4.8pp	20.8%-3.4pp	24.1%+6.1pp	18.1%-35.0pp	53.1%+8.3pp	44.8%+12.9pp	31.9%	106.9%	-382.1%	-939.3%	-641.2%	-265.3%	-55.3%

Metric	Q2'27	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25
Gross Margin	96.7%0.0pp	96.7%+1.2pp	95.6%-1.3pp	96.9%+0.3pp	96.6%0.0pp	96.5%+0.1pp	96.5%-0.3pp	96.8%
Operating Margin	39.5%-1.6pp	41.1%+1.9pp	39.3%-0.3pp	39.6%+2.0pp	37.6%+3.9pp	33.6%+4.8pp	28.8%+3.6pp	25.2%
Net Margin	33.7%-0.7pp	34.5%-6.4pp	40.8%+8.5pp	32.4%-0.2pp	32.5%+3.8pp	28.7%+4.1pp	24.7%+2.8pp	21.9%
Return on Equity	11.5%+0.6pp	10.9%-0.4pp	11.3%+2.4pp	9.0%-0.1pp	9.1%+1.6pp	7.5%+1.3pp	6.2%+1.1pp	5.2%
Return on Assets	8.5%+0.4pp	8.1%-0.5pp	8.6%+1.7pp	6.9%0.0pp	6.9%+1.3pp	5.6%+0.9pp	4.8%+0.8pp	4.0%
Current Ratio	3.46+0.2x	3.26-0.3x	3.56-0.2x	3.75+0.2x	3.510.0x	3.50-0.1x	3.63-0.3x	3.93
Debt-to-Equity	0.350.0x	0.340.0x	0.320.0x	0.310.0x	0.320.0x	0.330.0x	0.310.0x	0.30
FCF Margin	47.9%+6.9pp	41.0%-14.5pp	55.5%+7.2pp	48.3%+40.2pp	8.1%-29.4pp	37.5%-4.2pp	41.7%-7.1pp	48.8%

Similar Companies

Ionis Pharmaceuticals IONS

$10.1B

Biomarin Pharmaceutical Inc BMRN

$12.5B

Bridgebio Pharma BBIO

$15.0B

Ascendis Pharma ASND

$16.3B

Summit Therapeutics Inc SMMT

$11.0B

Where Exelixis Inc Ranks

Frequently Asked Questions

What is Exelixis Inc's annual revenue?

Exelixis Inc (EXEL) reported $2.3B in total revenue for fiscal year 2025. This represents a 7.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Exelixis Inc's revenue growing?

Exelixis Inc (EXEL) revenue grew by 7.0% year-over-year, from $2.2B to $2.3B in fiscal year 2025.

Is Exelixis Inc profitable?

Yes, Exelixis Inc (EXEL) reported a net income of $782.6M in fiscal year 2025, with a net profit margin of 33.7%.

What is Exelixis Inc's EBITDA?

Exelixis Inc (EXEL) had EBITDA of $901.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Exelixis Inc's gross margin?

Exelixis Inc (EXEL) had a gross margin of 96.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Exelixis Inc's operating margin?

Exelixis Inc (EXEL) had an operating margin of 37.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Exelixis Inc's net profit margin?

Exelixis Inc (EXEL) had a net profit margin of 33.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Exelixis Inc's return on equity (ROE)?

Exelixis Inc (EXEL) has a return on equity of 36.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Exelixis Inc's free cash flow?

Exelixis Inc (EXEL) generated $875.8M in free cash flow during fiscal year 2025. This represents a 30.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Exelixis Inc's operating cash flow?

Exelixis Inc (EXEL) generated $884.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Exelixis Inc's total assets?

Exelixis Inc (EXEL) had $2.8B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Exelixis Inc's capital expenditures?

Exelixis Inc (EXEL) invested $8.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Exelixis Inc spend on research and development?

Exelixis Inc (EXEL) invested $825.0M in research and development during fiscal year 2025.

Does Exelixis Inc buy back shares?

Yes, Exelixis Inc (EXEL) spent $947.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Exelixis Inc have outstanding?

Exelixis Inc (EXEL) had 260M shares outstanding as of fiscal year 2025.

What is Exelixis Inc's current ratio?

Exelixis Inc (EXEL) had a current ratio of 3.56 as of fiscal year 2025, which is generally considered healthy.

What is Exelixis Inc's debt-to-equity ratio?

Exelixis Inc (EXEL) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Exelixis Inc's return on assets (ROA)?

Exelixis Inc (EXEL) had a return on assets of 27.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Exelixis Inc's Altman Z-Score?

Exelixis Inc (EXEL) has an Altman Z-Score of 14.08, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Exelixis Inc's Piotroski F-Score?

Exelixis Inc (EXEL) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Exelixis Inc's earnings high quality?

Exelixis Inc (EXEL) has an earnings quality ratio of 1.13x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Exelixis Inc?

Exelixis Inc (EXEL) scores 80 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.